# NANOVIRICIDES, INC. (NNVC) · Edgar & Edgarette company card

> Nanoviricides, Inc. (NNVC) reported revenue of $0 million in FY2026, operating margin null against a -3.8% median for pharmaceutical preparations, equity 87.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1379006 · fiscal year ended 2026-06-30 · 4 audited years read · [page](https://www.pops4.com/boards/company/NNVC) · [JSON](https://www.pops4.com/boards/company/NNVC.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$8M |
| Capital spending | $84,317 |
| Free cash flow | −$8M |
| Cash | $3M |
| Long-term debt | — |
| Total assets | $10M |
| Total equity | $9M |
| Equity ÷ assets | 87.9% |
| Return on equity | -94.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -48.6 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$7.7M in FY2026); operating loss: a margin of -Infinity% in FY2026

## Edgarette's reading

Exposure: revenue $0K (FY2026). Experience: one year on record; operating margin null, up from null. Soundness: equity 87.9% of assets, return on equity -94.7%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-09-29 ([filing](https://www.sec.gov/Archives/edgar/data/1379006/000110465926111952/0001104659-26-111952-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-08 · [filing](https://www.sec.gov/Archives/edgar/data/1379006/000110465926114606/0001104659-26-114606-index.htm)
- 8-K · filed 2026-09-29 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1379006/000110465926111952/0001104659-26-111952-index.htm)
- 10-K · filed 2026-09-28 · [filing](https://www.sec.gov/Archives/edgar/data/1379006/000110465926111390/0001104659-26-111390-index.htm)
- 8-K · filed 2026-07-30 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1379006/000110465926088393/0001104659-26-088393-index.htm)
- 8-K · filed 2026-07-17 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1379006/000110465926084668/0001104659-26-084668-index.htm)
- 8-K · filed 2026-05-21 · 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/1379006/000110465926064754/0001104659-26-064754-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001379006.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1379006

## Cite

POPS4, Edgar & Edgarette: NANOVIRICIDES, INC. (NNVC) company card, from the company's own SEC filings, accessed 2026-11-15, https://www.pops4.com/boards/company/NNVC. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.